HippoFi (formerly ORHub) signed a strategic agreement with Precision Spine relating to the PUR Biologics line of products.
HippoFi’s regenerative therapeutics division, PUR Biologics, is focused on advanced biological solutions for spine surgery and provides Precision Spine the ability to immediately sell a full line of biologic products alongside their broad spine implant portfolio.
“This agreement will help to accelerate growth and drive revenue by selling the entire PUR Biologics product line and future HippoFi innovations. With Precision’s strong presence in the Spine market, we expect a substantial increase in our revenues and brand recognition,” said CJ Wiggins, Executive Chairman & CEO of HippoFi.
“This deal allows HippoFi to drive new sales through Precision’s vast and growing network, which already includes revenue producing accounts with more than 280 hospitals and approximately 340 spine surgeons. I expect this partnership will bring the speed and product commercialization we are looking for with Precision’s 180+ sales distributors,” said Ryan Fernan, Head of PUR Biologics. “I am excited to work with Precision Spine’s seasoned commercial team to bring our premium products and future technologies to patients and surgeons.”
HippoFi (formerly ORHub) signed a strategic agreement with Precision Spine relating to the PUR Biologics line of products.
HippoFi's regenerative therapeutics division, PUR Biologics, is focused on advanced biological solutions for spine surgery and provides Precision Spine the ability to immediately sell a full line of biologic products...
HippoFi (formerly ORHub) signed a strategic agreement with Precision Spine relating to the PUR Biologics line of products.
HippoFi’s regenerative therapeutics division, PUR Biologics, is focused on advanced biological solutions for spine surgery and provides Precision Spine the ability to immediately sell a full line of biologic products alongside their broad spine implant portfolio.
“This agreement will help to accelerate growth and drive revenue by selling the entire PUR Biologics product line and future HippoFi innovations. With Precision’s strong presence in the Spine market, we expect a substantial increase in our revenues and brand recognition,” said CJ Wiggins, Executive Chairman & CEO of HippoFi.
“This deal allows HippoFi to drive new sales through Precision’s vast and growing network, which already includes revenue producing accounts with more than 280 hospitals and approximately 340 spine surgeons. I expect this partnership will bring the speed and product commercialization we are looking for with Precision’s 180+ sales distributors,” said Ryan Fernan, Head of PUR Biologics. “I am excited to work with Precision Spine’s seasoned commercial team to bring our premium products and future technologies to patients and surgeons.”
Copy to clipboard 
